Indication for symptomatic VMA
ThromboGenics has announced that the US Food and Drug Administration (FDA) has approved JETREAR (ocriplasmin) in the US for the treatment of symptomatic VMA. Dr Patrik De Haes, CEO of ThromboGenics, said: “The FDA approval of JETREAR is a major milestone for the company. We are extremely pleased that we will be able to meet a major unmet clinical need in ophthalmology when we make JETREAR, the first pharmacological agent for symptomatic VMA, available to the many thousands of US patients who could benefit from treatment of this progressive, sight-threatening condition. We are continuing to prepare for the planned launch of JETREAR in January 2013 through our own US commercial organisation. This is the biggest step in transforming ThromboGenics into a profitable biopharmaceutical company developing and commercialising innovative ophthalmic medicines,†said Dr De Haes. Â
•  www.thrombogenics.comÂ
Latest Articles
Beyond the Numbers
Empowering patient participation fosters continuous innovation in cataract surgery.
Thinking Beyond the Surgery Room
Practice management workshop focuses on financial operations and AI business applications.
Aid Cuts Threaten Global Eye Care Progress
USAID closure leads retreat in development assistance.
Supplement: ESCRS Clinical Trends Series: Presbyopia
Nutrition and the Eye: A Recipe for Success
A look at the evidence for tasty ways of lowering risks and improving ocular health.
New Award to Encourage Research into Sustainable Practices
Sharing a Vision for the Future
ESCRS leaders update Trieste conference on ESCRS initiatives.
Extending Depth of Satisfaction
The ESCRS Eye Journal Club discuss a new study reviewing the causes and management of dissatisfaction after implantation of an EDOF IOL.
Conventional Versus Laser-Assisted Cataract Surgery
Evidence favours conventional technique in most cases.
AI Scribing and Telephone Management
Automating note-taking and call centres could boost practice efficiency.